Overview

• Mass General Brigham researchers confirm HPV-DeepSeek's 99% sensitivity and specificity for diagnosing HPV-associated head and neck cancers at first clinical presentation.
• The test uses whole-genome sequencing of the entire HPV genome, surpassing current liquid biopsy methods that target only one or two viral sequences.
• A study published in Clinical Cancer Research demonstrated HPV-DeepSeek's superior accuracy compared to existing diagnostic approaches in a trial involving 152 patients and 152 healthy controls.
• A preprint study revealed the test detected cancer in 79% of individuals up to eight years before clinical diagnosis, with no false positives among controls.
• Ongoing trials are exploring HPV-DeepSeek's potential for pre-symptomatic cancer screening and postoperative monitoring of minimal residual disease to guide treatment decisions.